Monoclonal antibodies : (Record no. 39594)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | nam a22 7a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 190410b2015 xxu||||| |||| 00| 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780081002964 |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.37 SHI-S |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Shire, Steven J. |
| 245 ## - TITLE STATEMENT | |
| Title | Monoclonal antibodies : |
| Remainder of title | meeting the challenges in manufacturing, formulation, delivery and stability of final drug product / |
| Statement of responsibility, etc. | Steven J. Shire |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication, distribution, etc. | Amsterdam |
| Name of publisher, distributor, etc. | Elsevier |
| Date of publication, distribution, etc. | 2015 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 203 p. |
| 365 ## - TRADE PRICE | |
| Price type code | USD |
| Price amount | 210.00. |
| 500 ## - GENERAL NOTE | |
| General note | Monoclonal antibodies (MAbs) are currently the major class of protein bio therapeutic being developed by biotechnology and pharmaceutical companies. Monoclonal Antibodies discusses the challenges and issues revolving around development of a monoclonal antibody produced by recombinant DNA technology into a therapeutic agent.This book covers downstream processing which includes design of processes to manufacture the formulation, formulation design, fill and finish into closure systems and routes of administration. The characterization of the final drug product is covered where the use of biophysical methods combined with genetic engineering is used to understand the solution properties of the formulation. The latter has become very important since many indications such as arthritis and asthma require the development of formulations for subcutaneous delivery (SC). The development of formulations for IV delivery is also important and comes with a different set of challenges. The challenges and strategies that can overcome these limitations are discussed in this book, starting with an introduction to these issues, followed by chapters detailing strategies to deal with them. Subsequent chapters explore the processing and storage of mAbs, development of delivery device technologies and conclude with a chapter on the future of mAbs in therapeutic remedies.<br/><br/><br/><br/>Discusses the challenges to develop MAbs for intravenous (IV) and subcutaneous delivery (SC)<br/>Presents strategies to meet the challenges in development of MAbs for SC and IV administration<br/>Discusses the use of biophysical analytical tools coupled with MAb engineering to understand what governs MAb properties at high concentration |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Monoclonal antibodies |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmaceutical technology |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Monoclonal antibodies--Therapeutic use |
| 952 ## - LOCATION AND ITEM INFORMATION (KOHA) | |
| Withdrawn status | |
| Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Collection code | Current library | Shelving location | Date acquired | Total Checkouts | Full call number | Barcode | Date last seen | Date last checked out | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | 610 | BITS Pilani Hyderabad | General Stack (For lending) | 10/04/2019 | 2 | 615.37 SHI-S | 38892 | 13/07/2024 | 19/05/2023 | Books |